Lanza F, Castoldi G L, Castagnari B, Todd R F, Moretti S, Spisani S, Latorraca A, Focarile E, Roberti M G, Traniello S
Department of Biomedical Sciences and Advanced Therapies, University of Ferrara, Italy.
Br J Haematol. 1998 Oct;103(1):110-23. doi: 10.1046/j.1365-2141.1998.00932.x.
Urokinase-type plasminogen activator receptor (UPA-R-CD87) is a GPI-anchored membrane protein which promotes the generation of plasmin on the surface of many cell types, probably facilitating cellular extravasation and tissue invasion. A flow cytometric quantitative analysis of expression levels for UPA-R was performed on fresh blast cells from patients with acute myeloid leukaemia (AML, n = 74), acute lymphoblastic leukaemia (ALL, n = 24), and biphenotypic leukaemia (BAL, n = 3) using two CD87 monoclonal antibodies (McAbs) (3B10 and VIM5). Peripheral blood and bone marrow (BM) cells from 15 healthy adults served as controls. Using 3B10 McAb, UPA-R was expressed (>99%) by blood monocytes, neutrophils, and BM myelomonocytic precursors in controls, whereas resting T and B lymphocytes, and CD34+ cells were UPA-R negative. We also attempted to clarify whether UPA-R has a role in mediating neutrophil functions. Oriented locomotion induced by different chemotaxins and lysozyme release by granules stimulated with fMLP or PMA were significantly decreased when UPA-R was neutralized by CD87 McAb. In contrast, the anti-UPA-R McAb had no effect on superoxide anion generation of normal neutrophils. Blasts from AML showed a heterogenous pattern of expression for the UPA-R McAbs, with reactivity strictly dependent on FAB subtype. The highest UPA-R expression was seen in the M5 group: all patients tested (n = 20) showed strong positivity for the UPA-R McAb whereas only 12% (3/24) of ALL patients were CD87 positive, and 2/3 of BAL patients showed a dim expression for CD87. The number of receptors expressed by blast cells in 6/74 (8.1%) AML patients was higher than those of normal samples: in addition, since co-expression of UPA-R and CD34 was not found in normal haemopoietic cells, it may be postulated that CD87 can be used alone (when overexpressed) or in combination with CD34 for the detection of minimal residual disease. Results also indicated that patients with UPA-receptors >12 x 10(3) ABC/cell, irrespective of FAB subtype, had a greater tendency for cutaneous and tissue infiltration and a higher frequency of chromosome abnormalities, thus suggesting the concept that cellular UPA-R content positively correlates with the invasive potential of AML cells. The combination of higher UPA-R positivity, abnormalities of chromosome 11, and M5 FAB morphology may identify a peculiar subset of AML, characterized by a more aggressive clinical course.
尿激酶型纤溶酶原激活物受体(UPA - R - CD87)是一种糖基磷脂酰肌醇(GPI)锚定的膜蛋白,它能促进多种细胞类型表面纤溶酶的生成,可能有助于细胞外渗和组织侵袭。使用两种CD87单克隆抗体(3B10和VIM5),对急性髓系白血病(AML,n = 74)、急性淋巴细胞白血病(ALL,n = 24)和双表型白血病(BAL,n = 3)患者的新鲜原始细胞进行了UPA - R表达水平的流式细胞术定量分析。15名健康成年人的外周血和骨髓(BM)细胞作为对照。使用3B10单克隆抗体,对照组中的血液单核细胞、中性粒细胞和BM髓单核细胞前体细胞表达UPA - R(>99%),而静息T和B淋巴细胞以及CD34 +细胞UPA - R呈阴性。我们还试图阐明UPA - R是否在介导中性粒细胞功能中起作用。当用CD87单克隆抗体中和UPA - R时,不同趋化因子诱导的定向运动以及fMLP或PMA刺激颗粒释放溶菌酶的能力均显著降低。相比之下,抗UPA - R单克隆抗体对正常中性粒细胞产生超氧阴离子没有影响。AML患者的原始细胞对UPA - R单克隆抗体呈现出异质性表达模式,其反应性严格依赖于FAB亚型。在M5组中观察到最高的UPA - R表达:所有检测患者(n = 20)对UPA - R单克隆抗体均呈强阳性,而ALL患者中只有12%(3/24)为CD87阳性,BAL患者中有2/3的CD87表达较弱。74例AML患者中有6例(8.1%)原始细胞表达的受体数量高于正常样本:此外,由于在正常造血细胞中未发现UPA - R和CD34的共表达,因此可以推测,CD87单独使用(过表达时)或与CD34联合使用可用于检测微小残留病。结果还表明,无论FAB亚型如何,UPA受体>12×10³ ABC/细胞的患者皮肤和组织浸润倾向更大,染色体异常频率更高,这表明细胞UPA - R含量与AML细胞的侵袭潜能呈正相关。UPA - R高阳性、11号染色体异常和M5 FAB形态的组合可能识别出一种特殊的AML亚型,其临床病程更具侵袭性。